Geron Presentations at Upcoming EHA Annual Meeting to Report Updated Durability, Disease Modification and Favorable Patient Reported Outcomes (PRO) in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3
Longer follow-up data for 1-year transfusion independence in IMerge Phase 3, which demonstrated statistically significant and clinically meaningful continuous, durable efficacy Strong... | May 11, 2023
Source: marketscreener.com